Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer
Conditions: Breast Cancer; Solid Tumor Intervention: Drug: OBT076, a CD205-directed antibody-drug conjugate Sponsor: Oxford BioTherapeutics Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials